Encore Vision completes enrollment for phase 1/2 trial of EV06 for presbyopia

Encore Vision has completed patient enrollment for a phase 1/2 trial of topical EV06 ophthalmic solution for the treatment of presbyopia, according to a press release. The prospective, randomized, doublemasked, multicenter trial will examine the safety and efficacy of EV06 (lipoic acid choline ester 1.5%) compared with placebo for 90 days to treat presbyopia.